TP53 and non-small cell lung carcinoma: ASCETIC confirmed the mutual exclusivity of some driver mutations, such as EGFR and KRAS38 or TP53 and KEAP139, clarified the timing relation between genomics alterations that are involved in lung carcinogenesis and allowed us to discover new late-occurring mutations that may have a relevant role in NSCLC progression.